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Abstract
Background
29 autoimmune diseases, including Rheumatoid Arthritis, gout, Crohn’s Disease, and Sys-
tematic Lupus Erythematosus affect 7.6-9.4% of the population. While effective therapy is
available, many patients do not follow treatment or use medications as directed. Digital
health and Web 2.0 interventions have demonstrated much promise in increasing medica-
tion and treatment adherence, but to date many Internet tools have proven disappointing. In
fact, most digital interventions continue to suffer from high attrition in patient populations,
are burdensome for healthcare professionals, and have relatively short life spans.
Objective
Digital health tools have traditionally centered on the transformation of existing interventions
(such as diaries, trackers, stage-based or cognitive behavioral therapy programs, coupons,
or symptom checklists) to electronic format. Advanced digital interventions have also incor-
porated attributes of Web 2.0 such as social networking, text messaging, and the use of
video. Despite these efforts, there has not been little measurable impact in non-adherence
for illnesses that require medical interventions, and research must look to other strategies
or development methodologies. As a first step in investigating the feasibility of developing
such a tool, the objective of the current study is to systematically rate factors of non-adher-
ence that have been reported in past research studies.
Methods
Grounded Theory, recognized as a rigorous method that facilitates the emergence of new
themes through systematic analysis, data collection and coding, was used to analyze quanti-
tative, qualitative and mixed method studies addressing the following autoimmune diseases:
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Rheumatoid Arthritis, gout, Crohn’s Disease, Systematic Lupus Erythematosus, and inflam-
matory bowel disease. Studies were only included if they contained primary data addressing
the relationship with non-adherence.
Results
Out of the 27 studies, four non-modifiable and 11 modifiable risk factors were discovered.
Over one third of articles identified the following risk factors as common contributors to med-
ication non-adherence (percent of studies reporting): patients not understanding treatment
(44%), side effects (41%), age (37%), dose regimen (33%), and perceived medication inef-
fectiveness (33%). An unanticipated finding that emerged was the need for risk stratification
tools (81%) with patient-centric approaches (67%).
Conclusions
This study systematically identifies and categorizes medication non-adherence risk factors
in select autoimmune diseases. Findings indicate that patients understanding of their dis-
ease and the role of medication are paramount. An unexpected finding was that the majority
of research articles called for the creation of tailored, patient-centric interventions that dispel
personal misconceptions about disease, pharmacotherapy, and how the body responds to
treatment. To our knowledge, these interventions do not yet exist in digital format. Rather
than adopting a systems level approach, digital health programs should focus on cohorts
with heterogeneous needs, and develop tailored interventions based on individual non-
adherence patterns.
Background
Digital Health Interventions
In the mid-1980’s research began to examine how digital technology could be facilitate
improved patient health [1,2]. Since then, evidence has indicated that many patients would
prefer to communicate with their physician via email [3], that patient-led Internet support sys-
tems can safely help with complex behavioral issues [4], and that physicians, payers and hospi-
tal systems could benefit by leveraging the Internet to improve communication amongst
stakeholders [5]. Several Cochrane reviews have indicated that digital health programs can be a
benefit to patients [6–10], however to our knowledge, the literature has not identified effective
digital programs for autoimmune disorders.
Digital health tools have traditionally centered on the transformation of existing paper-
based interventions (such as diaries, trackers, stage-based or cognitive behavioral therapy pro-
grams, web-based coupon downloads, or symptom checklists) to electronic format. Advanced
digital interventions have also incorporated attributes of Web 2.0 such as social networking,
text messaging, and the use of video. However, Internet interventions typically have high attri-
tion and have so far failed to produce population effects [11–13].
To further complicate matters, failures to deliver effective systems, tools and interventions
have been reported in countries traditionally associated with high Internet adoption rates.
Countries such as Australia [14,15], Canada [16,17], the United Kingdom [18,19] and the
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United States [20–22] have all reported massive eHealth failures, and the potential of digital
health remains unrecognized.
The Adherence Problem
A well-known, systemic problem in healthcare is medication non-adherence. The World
Health Organization estimates that the average non-adherence rate in developed countries is
50% among patients with chronic conditions [23]. Other studies estimate that non-adherence
in North American accounts for $300 billion dollars in avoidable costs, annually [24–26].
Non-adherence is a complex problem. At the patient level, medication non-adherence is
generally defined as intentional or non-intentional [27]. Strongly associated with personal
beliefs and perceptions, patients actively choose to ignore treatment in intentional non-adher-
ence, whereas unintentional non-adherence involves a passive process [28,29]. Risk factors in
treatment are well reported in the literature [30–32] and are generally labeled asmodifiable
(behavior-based) or non-modifiable (eg. age, gender).
Identifying a patient’s unique non-adherence patterns is time consuming, and existing
paper-based processes that require scoring, are complex and often expensive to administer.
Digital Health Interventions and Non-Adherence
One of the most attractive aspects of digital health is the ability to use algorithms to tailor inter-
ventions to individual preferences [33–35]. However, and as mentioned previously, most inter-
ventions are based on traditional approaches designed for large homogenous populations.
Rather than adopting a systems-level approach, digital health might focus on cohorts with
heterogeneous needs, and develop tailored interventions based to individual non-adherence
patterns.
To our knowledge, publicly-available digital health tools designed to target specific non-
adherence behaviors in autoimmune diseases do not exist. As a first step in investigating the
feasibility of developing such a tool, the objective of the current study is to systematically rate
factors of non-adherence that have been reported in past research studies.
Although several risk factors are well known (cost, forgetfulness, co-morbidities), they have
yet to be grouped, ranked or systematically categorized. To uncover common risk factors
observed by researchers, we systematically reviewed qualitative, quantitative and mixed-meth-
ods literature that reported factors noted in their respective cohorts.
Recognized as a rigorous method to facilitate the emergence of common themes in previ-
ously published literature, we used Grounded Theory (GT) as process to uncover these factors
[36]. Before describing the specific GT methodology used in our research, an outline of the
magnitude of non-adherence among autoimmunology stakeholders will be first presented.
The Adherence Problem
Approximately 8–9% of the population is affected by 29 autoimmune diseases, including Rheu-
matoid Arthritis (RA), gout, Crohn’s Disease (CD), and Systemic Lupus Erythematosus (SLE)
[37]. As is typical with chronic conditions, many patients do not adhere to long-term therapies.
In autoimmunology, reported estimates of non-adherence in research studies range from
7–84% [38–40]. This wide range can be attributed to difficulties in both recording individual
rates of non-adherence, and a lack of measurement standards.
Traditional research methods used to measure medication adherence include patient self-
report, Electronic Monitoring (EM), and direct observation. Although EM is most accurate,
patient self-report and EMmay be unreliable as they are potentially subject to the Hawthorne
Digital Health and Non-Adherence in Immunology
PLOS ONE | DOI:10.1371/journal.pone.0129364 June 24, 2015 3 / 17
effect [41] (i.e., adherence behavior changes as a result of being monitored, and some research-
ers choose to not inform patients of monitoring to avoid the observation effect).
In retrospective database studies, adherence is most commonly reported in terms of Medi-
cation Possession Ratios (MPR) and/or Proportion of Days Covered (PDC). Deriving MPR
and PDC requires access to patient-level treatment utilization data, which is typically retro-
spective. MPR and PDC are not necessarily accurate, as it cannot be guaranteed that patients
are following treatment simply because they are fulfilling prescriptions or collecting medication
at expected intervals [42].
The only current means to ensure adherence is by direct observation without patient knowl-
edge [43,44]. Unfortunately, this method is difficult to replicate and perform on a large scare,
so true non-adherence rates may be impossible to estimate.
Costs Related to Non-Adherence
As in other chronic conditions, non-adherence rates in autoimmunology lead to increased
costs throughout healthcare systems. Costs resulting from the progression of disease and the
subsequent need for more aggressive treatment also result in significant economic burden [45],
and when immunological diseases are comorbid with other conditions, non-adherence to
proven treatment increased health risks and costs for both disorders [46].
Likewise, adherent patients contribute to positive health benefits and economic outcomes.
For example, a cohort study of 834 SLE patients found that decreased adherence led to
increased visits to rheumatologists, primary care physicians, other care provides, emergency
departments, and hospitalizations [47]. While adherence resulted in shorter hospital length of
stay and lower inpatient costs in CD patients in one study [48], another discovered that when
compared to adherent ulcerative colitis patients, those who were non-adherent incurred twice
the inpatient costs and significantly greater overall health care costs [49].
Methods
Rigorously reviewing literature with Grounded Theory
Founded by Glaser and Strauss in 1967, GT is an objectivist methodology used to develop theo-
retical interpretations without defining phenomenon a priori [50]. In conducting GT, research-
ers first familiarize themselves with prior research to determine a general research question,
followed by a mechanistic review and classification of data [51]. As it is a research method
involving discovery through systematic analysis, data collection and coding [52], past studies
have recognized GT as a method to study social psychological themes across diverse chronic ill-
nesses [53].
To uncover themes in previously published research, this study utilized the five-stage pro-
cess outlined by Wolfswinkel et al. to conduct a rigorous literature review (Define, Search,
Select, Analyze, Present) [36]. When followed correctly, this process assures an in-depth analy-
sis of empirical facts, interrelationships and dependencies beyond a particular area, and the
emergence of themes. In addition, this review followed the Preferred Reporting Items for Sys-
tematic Reviews and Meta-Analyses (PRISMA) checklist for systematic reviews [54]. The
PRISMA flow diagram is provided in Fig 1. The PRISMA checklist is provided in S1 PRISMA
Checklist.
Database and search methodology (Define, Search). In the Define stage, we conducted a
general literature review of various issues related to medication non-adherence over a number
of chronic disease conditions. Initial findings primarily centered on recurring problems related
to lack of defined terminologies (adherence, compliance, persistence, concordance) [55,56],
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delivery mechanisms (oral, subcutaneous, infusion), dose measurement [42], the doctor-
patient relationship [57], and the ineffective nature of existing interventions [58,59].
During the Search stage, the databases PubMed and Google Scholar were searched in May
2013. PubMed was selected as it is a standardized database frequently referenced by physicians
to seek information, and Google Scholar was utilized as it has recently been identified as an
accurate reference for quick clinical searches [60].
As mentioned previously, there are 29 autoimmune diseases, and the literature on all of
these disorders is vast. Likewise, the research on non-adherence and related terminology (e.g.
compliance, concordance, discordance, persistence, shared decision-making, the therapeutic
alliance), delivery mechanisms and does regimen is also voluminous. In order to gain insight
on the research question and to simplify the search process, we limited MeSH keywords to a
subset of autoimmune disorders.
The keywords rheumatoid arthritis, rheumatology, gout, crohn’s disease, systematic lupus
erythematosus, inflammatory bowel disease andmedication adherence were used in the search
process. The initial database search returned 816 records. Following the removal of duplicates,
581 abstracts were included for further analysis.
Study selection (Select). For the purpose of knowledge generation, meta-analyses,
Cochrane reviews, case studies, reports, letters to the editor and opinion articles were reviewed
in the initial screening process, but to synthesize results and remove the possibility of replica-
tion, were excluded in the coding process.
Fig 1. PRISMA flow diagram.
doi:10.1371/journal.pone.0129364.g001
Digital Health and Non-Adherence in Immunology
PLOS ONE | DOI:10.1371/journal.pone.0129364 June 24, 2015 5 / 17
Fig 1 presents the PRISMA flow chart for the selection of included studies. Articles were
included for eligibility coding if they met the following criteria:
1. Peer-reviewed studies reporting primary data only.
2. Quantitative (e.g. as measured by MPR or PDC), qualitative (e.g. through the use of surveys
or interviews), and mixed-methods studies that measured adherence within autoimmunol-
ogy indications.
3. Articles in English language only
4. Any jurisdiction or geographical location.
Study selection was conducted in two stages—initial screening (TvM) and subsequent vali-
dation by a second researcher (RF). The first researcher screened the 581 abstracts, confirming
519 did not meet study criteria, resulting in 62 potentially relevant studies. The Select process
then required a full examination of the 62 articles. Following full examination, a further 34 arti-
cles were discarded, leaving 28 studies that met all inclusion criteria. Double-checking this pro-
cess with the second researcher resulted in the further exclusion of one additional study,
leaving 27 studies.
Coding of studies (Analyze). As recommended by Wolfswinkel et al, open, axial and
selective coding was applied systematically to all included studies. In open coding, researchers
reviewed the 27 studies to develop and categorize meta-insights and concepts. Following this,
all studies were re-reviewed and re-coded to investigate the consistency of meta-insights and
themes (axial coding), resulting in the establishment of main themes and patterns. Finally,
researchers performed selective coding where theoretical saturation of themes and patterns
was established. As outlined in GT study protocol, a reliability check was conducted to confirm
risk factor identification, coding procedure, scoring, and results [61]. Each study was coded
with NVivo qualitative data analysis software, version 10.
Risk factors were only coded if they were explicitly noted in the Results, Discussion or the
Conclusion section of each study. If a risk factor was identified in a study it received a score of
one. Even if the risk factor was noted numerous times in each study, the maximum score a risk
factor could receive in a single study was one (Table 1).
Analysis strategy (Present). Following the reliability check, coding was synthesized to for-
mulate a holistic set of findings and insights that are specific to understanding why, despite
proven efficacy of treatment, autoimmunology patients are typically non-adherent.
Results
The characteristics of studies varied and included retrospective database analyses, patient sur-
veys, cross-sectional assessments, longitudinal studies, questionnaires, patient interviews, feasi-
bility surveys, telephone surveys, laboratory tests, multidisciplinary task groups and electronic
monitoring. Type of study also varied, with six quantitative, 12 qualitative and nine mixed-
method studies (Tables 2 and 3). This variation contributed to the aim of this study as strong
common themes emerged across vastly different study designs.
Studies were published between 1990 and 2012. Twelve studies were based on study popula-
tions within North America (11 USA, one Mexico), 13 studies were based on Western/Eastern
Europe and Middle East populations (10 Western Europe, two Eastern Europe and one Middle
East), and two studies were based on AustralAsia populations (two New Zealand). Twelve stud-
ies focused on RA patients, six in IBD, five in SLE, three in Gout, and one in UC.
Out of the 27 studies, four non-modifiable and 11 modifiable risk factors were uncovered
(Fig 2. and Tables 2 and 3). The four non-modifiable risk factors were age, race/ethnicity,
Digital Health and Non-Adherence in Immunology
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Table 1. Summary of Studies Reporting Factors of Non-Adherence (n = 27).
Citation Research Method/Sample Country of
Origin
Disease Non-Adherence Factor(s) Listed / Recommended
Approach
Bermejo et al.,
2010
Survey (N = 107) Spain Inﬂammatory bowel
disease
Patient does not understand treatment, Forgetfulness
or inconvenience, Dose regimen Lack of motivation or
social support, Risk stratiﬁcation tool or intervention
recommended, Patient-centric approach recommended
Cannon et al.,
2011
Retrospective database
(N = 1412)
USA Rheumatoid arthritis Ethnicity, Gender (females less adherent), Disease
severity, Risk stratiﬁcation tool or intervention
recommended
Dalbeth et al.,
2012
Cross sectional assessment
(N = 273)
New Zealand Gout Ethnicity, Gender (males less adherent), Patient does
not understand treatment, Lack of motivation or social
support, Disease severity, Risk stratiﬁcation tool or
intervention recommended, Patient-centric approach
recommended
de Turrah et al.,
2010
Longitudinal study (N = 941) Denmark Rheumatoid arthritis Disease duration, Perceived medication
ineffectiveness, Disease severity, Comorbid conditions,
Risk stratiﬁcation tool or intervention recommended
de Turrah et al.,
2010
Retrospective database,
questionnaire (N = 126)
Denmark Rheumatoid arthritis Disease duration, Patient does not understand
treatment, Perceived medication ineffectiveness, Risk
stratiﬁcation tool or intervention recommended
Daleboudt et al.,
2011
Questionnaire (N = 106) New Zealand Systemic lupus
erythematosus
Age, Ethnicity, Patient does not understand treatment,
Side effects Forgetfulness or inconvenience, Mood
disorder, Risk stratiﬁcation tool or intervention
recommended, Patient-centric approach recommended
Garcia-Gonzalez
et al., 2008
Cross-sectional survey
(N = 102)
USA Rheumatoid arthritis and
systemic lupus
erythematosus
Ethnicity, Side-effects, Perceived medication
ineffectiveness, Patient-centric approach
Harrold et al.,
2010
Interview (N = 26) USA Gout Side-effects, Perceived medication ineffectiveness,
Lack of motivation or social support, Cost, Risk
stratiﬁcation tool or intervention recommended, Patient-
centric approach recommended
Harrold et al.,
2009
Retrospective database
(N = 4166)
USA Gout Age (older more adherent), Comorbid conditions, Risk
stratiﬁcation tool or intervention recommended, Patient-
centric approach recommended
Hetland et al.,
2012
Retrospective database,
questionnaire (N = 2326)
Denmark Rheumatoid arthritis Age (younger more adherent), Side effects, Perceived
medication ineffectiveness
Horne et al.,
2009
Cross sectional survey
(N = 1871)
USA Inﬂammatory bowel
disease
Age (older more adherent), Disease duration, Patient
does not understand treatment, Side-effects,
Forgetfulness or inconvenience, Dose regimen,
Perceived mediation ineffectiveness Disease severity,
Risk stratiﬁcation tool or intervention recommended,
Patient-centric approach recommended
Hughes et al.,
2011
Feasibility survey (N = 112) United
Kingdom
Rheumatoid arthritis Forgetfulness or inconvenience, Risk stratiﬁcation tool
or intervention recommended
Julian et al.,
2009
Retrospective database,
Telephone survey (N = 834)
USA Systemic lupus
erythematosus
Disease duration, Forgetfulness or inconvenience,
Dose regimen, Mood disorder, Risk stratiﬁcation tool or
intervention recommended, Patient-centric approach
recommended
Koneru et al.,
2008
Retrospective database,
questionnaire (N = 63)
USA Systemic lupus
erythematosus
Ethnicity, Patient does not understand treatment,
Forgetfulness or inconvenience, Dose regimen,
Forgetting instructions, Mood disorder, Lack of
motivation or social support, Comorbid conditions,
Cost, Risk stratiﬁcation tool or intervention
recommended, Patient-centric approach recommended
Kamperidis et al.,
2012
Retrospective database
(N = 238)
United
Kingdom
Inﬂammatory bowel
disease
Age (younger less adherent), Comorbid conditions,
Risk stratiﬁcation tool or intervention recommended
(Continued)
Digital Health and Non-Adherence in Immunology
PLOS ONE | DOI:10.1371/journal.pone.0129364 June 24, 2015 7 / 17
gender, and disease duration. The 11 modifiable risk factors included patients not understand-
ing treatment, side effects / adverse events, forgetfulness / inconvenience, dose regimen, for-
getting instructions, medication ineffectiveness, presence of a mood disorder, lack of
motivation or social support, disease severity, cost, and presence of a comorbid condition.
Across all study types and indications, the most commonly described determinants of medi-
cation non-adherence, confirmed in33% of studies, were patients not understanding
Table 1. (Continued)
Citation Research Method/Sample Country of
Origin
Disease Non-Adherence Factor(s) Listed / Recommended
Approach
Lakotos et al.,
2010
Questionnaire (N = 655) Hungary Inﬂammatory bowel
disease
Side effects, Forgetfulness or inconvenience, Dose
regimen, Risk stratiﬁcation tool or intervention
recommended, Patient-centric approach recommended
Li et al., 2010 Retrospective database USA Rheumatoid arthritis Ethnicity, Side effects, Dose regimen
Lorish et al.,
1990
Interview (N = 140) United
Kingdom
Rheumatoid arthritis Patient does not understand treatment, Side effects,
Forgetfulness or inconvenience, Dose regimen,
Perceived mediation ineffectiveness, Risk stratiﬁcation
tool or intervention recommended, Patient-centric
approach recommended
Marengo et al.,
2012
Questionnaire, laboratory
testing, electronic monitoring
(N = 78)
USA Systemic lupus
erythematosus
Patient does not understand treatment, Dose regimen,
Mood disorder, Comorbid conditions, Risk stratiﬁcation
tool or intervention, recommended, Patient-centric
approach recommended
Muller et al.,
2012
Questionnaire (N = 1199) Estonia Rheumatoid arthritis Age (younger less adherent), Patient does not
understand treatment, Side effects, Forgetting
instructions, Patient-centric approach recommended
Moshkovska
et al., 2009
Questionnaire, laboratory
testing (N = 169)
United
Kingdom
Ulcerative colitis Age (younger less adherent), Ethnicity Side effects,
Risk stratiﬁcation tool or intervention recommended,
Patient-centric approach recommended
Nahon et al.,
2012
Questionnaire (N = 1663) France Inﬂammatory bowel
disease
Mood disorder, Risk stratiﬁcation tool or intervention
recommended
Nguyen et al.,
2009
Retrospective database,
Cross sectional (N = 235)
USA Inﬂammatory bowel
disease
Age (younger less adherent), Ethnicity, Risk
stratiﬁcation tool or intervention recommended, Patient-
centric approach recommended
Pascual-Ramos
et al., 2009
Retrospective database,
interview (N = 75)
Mexico Rheumatoid arthritis Age (older less adherent), Forgetting instructions,
Patient-centric approach recommended
Richards et al.,
2012
Retrospective database
(N = 1372)
USA Rheumatoid arthritis Ethnicity, Dose regimen, Risk stratiﬁcation tool or
intervention recommended
Tuncay et al.,
2007
Questionnaire (N = 100) Turkey Rheumatoid arthritis Age (younger less adherent), Disease severity, Risk
stratiﬁcation tool or intervention recommended, Patient-
centric approach recommended
Zwikker et al.,
2012
A multidisciplinary tasks
group
The
Netherlands
Rheumatoid arthritis Patient does not understand treatment, Side effects,
Lack of motivation or social support, Risk stratiﬁcation
tool or intervention recommended, Patient-centric
approach recommended
doi:10.1371/journal.pone.0129364.t001
Table 2. Non-modifiable Risk Factors.
Total Number of Studies Age Ethnicity Disease Duration Gender
Quantitative Studies (n) % 6 (2) 33% (2) 33% (2) 33% (0) 0%
Qualitative Studies (n) % 12 (4) 33% (3) 23% (1) 8% (1) 8%
Mixed Studies (n) % 9 (4) 44% (4) 44% (2) 22% (1) 11%
Total (n) % 27 (10) 37% (9) 33% (5) 19% (2) 7%
doi:10.1371/journal.pone.0129364.t002
Digital Health and Non-Adherence in Immunology
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treatment (44%), side effects (41%), age (37%), dose regimen (33%), forgetfulness/inconve-
nience (33%), perceived medication ineffectiveness (33%) and ethnicity (33%).
Specifically looking at the 37% of studies reporting age as a non-modifiable factor, 30% indi-
cated that adherence increased as age progressed, while 7% indicated that younger people were
more adherent (Table 4).
Limiting studies to US-based populations only (n = 11), the most common modifiable fac-
tors (reported in33% of studies) were dose regimen (55%), and patients not understanding
treatment (45%), with side effects and perceived medication ineffectiveness at 36%. Ethnicity
(55%) was the most common non-modifiable factor.
The most common factors (reported in50% of studies) in RA specific studies conducted
in the USA (n = 4) were dose regimen (75%), ethnicity (50%), patients not understanding treat-
ment (50%) and co-morbid conditions (50%).
Fig 2. Proportion of studies reportingmodifiable and non-modifiable risk factors.
doi:10.1371/journal.pone.0129364.g002
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An unexpected finding was that the vast majority of study authors overwhelmingly advo-
cated for the development of risk stratification tools (81% of reported studies) with a patient-
centric approach (67% of reported studies) (Table 5).
Despite variations in study characteristics, year, location and differing target groups, recom-
mendations for risk-stratification tools and a patient-centric approach appeared in the majority
of studies.
Discussion
As we uncover the factors leading to non-adherence, we can begin to build profiles and digitally
tailor content. Past research has shown that clinical characteristics can be used to maximize
website utilization, and that short, tailored exercises may attract a wider audience [62]. How-
ever, this has not been attempted in autoimmunology.
Three of the five modifiable risk factors (not understanding treatment, perceived medica-
tion ineffectiveness and forgetfulness/inconvenience) could be addressed through targeted
patient communications, shared decision making tools, or more regular patient interaction
[63]. The relationship between side effects and non-adherence is longstanding across many
therapeutic areas [64–70], and might be a central focus of program content (e.g. support group
discussions or text messages).
Forgetfulness and inconvenience were frequently cited in the literature (33% of studies).
While text messaging and email reminders could manage general forgetfulness, auto-immune
diseases are serious and often painful, so it is most likely important to consider behavioral
motivations behind non-adherence. Immunological disorders and medicine are understand-
ably inconvenient, however as noted by the WHO [23], the long-term consequences of non-
adherence compromise patient safety and quality of life. Digital tools should be not be
Table 5. Recommended Treatment Approaches.
Total Number
of Studies (N)
Articles advocating for the
need for a risk stratiﬁcation
tool or intervention
Articles advocating for a
patient-centric approach to
treatment for non-adherence
Quantitative
Studies (n) %
6 (5) 83% (2) 33%
Qualitative
Studies (n) %
12 (10) 83% (10) 83%
Mixed Studies
(n) %
9 (7) 78% (6) 67%
Total (n) % 27 (22) 81% (18) 67%
doi:10.1371/journal.pone.0129364.t005
Table 4. Sub-set of age.
Total Number of
Studies (N)
Age Younger age more
adherent
Older age more
adherent
Number of Quantitative
Studies (n) %
6 (2)
33%
(0) 0% 2 (33%)
Number of Qualitative
Studies (n) %
12 (4)
33%
(0) 0% 4 (31%)
Number of Mixed Studies
(n) %
9 (4)
44%
2 (22%) 2 (22%)
Total (n) % 27 (10)
37%
2 (7%) 8 (30%)
doi:10.1371/journal.pone.0129364.t004
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paternalistic, and allow patients to make cost-benefit decisions in collaboration with their
physicians.
Five studies found that non-adherence increased as the frequency of dosing increased
[44,71–74], two studies indicated that non-adherence increased as regimens became more
complex [47,75], and one found a negative relationship between adherence and duration of
therapy [76]. In 2010, Li et al found that infusion patients were more adherent than those on
injection schedules, and also attributed increased adherence to decreased frequency of adminis-
tration and clinical assistance from physicians or nurses [45]. From these results it is clear that
digital interventions need to be tailored to medication dose frequency.
In the past, significant effort to address non-adherence has been placed on reducing costs to
patients and providing patients with detailed instructions on drug application. However, our
findings indicate that cost (7%) and forgetting instructions (11%) were less impactful than
other modifiable factors. The impact of cost on an individual or families’ decision to pursue
treatment is difficult to measure, especially in the complex US market where there is a paucity
of empirical evidence explaining how demand and supply prices influence utilization [77].
Interventions that focus on how and when to administer medication have also proven to be
ineffective [78]. Based on our results, the impact of efforts spent at circumventing cost (down-
loadable coupons, assistance programs) and providing instructions (printouts, detail aids)
should be reassessed, or be considered as part of a holistic framework of activities designed to
address the issue of non-adherence.
Given the tremendous health and economic costs attributed to medication non-adherence
in autoimmune diseases, the vast majority of publications (81%) identified the need for risk
stratification tools or interventions that are patient–centric (67%). Risk stratification tools exist
today, but they are largely physician-focused and have yet to be digitized. Some examples typi-
cally used in autoimmunology are the Compliance Questionnaire Rheumatology [79], the
Medication Adherence Rating Scale [80], the Morisky Medication Adherence Scale [81] and
the Rheumatoid Arthritis Severity Scale [82]. As in other condition areas, these standardized
tools and assessments can be modified to provide targeted feedback for both patients and pro-
viders [59,78,83–85].
However, careful consideration of process and design must be considered when developing
patient-centric interventions. Past attempts in autoimmunology showed that physician aware-
ness alone was necessary but not sufficient to improve adherence [86], and interventions may
have no impact on patient adherence or quality of life [58].
Limitations and Future Considerations
Limitations are similar to other research employing a GT approach. Only non-adherence risk
factors reported in the literature were included and categorized; risk factors not listed within
the works may very well exist and outweigh the factors outlined in this study. Regardless, these
study results summarize the risk factors supported by the current evidence base and can be eas-
ily articulated to experts in non-medical occupations such as website designers, project manag-
ers marketers.
Another possible limitation is the inclusion of both quantitative and qualitative studies;
modifiable risk factors such as forgetfulness or lack of motivation or social support cannot be
measured quantitatively. However, despite this limitation it is important to note that forgetful-
ness or inconvenience was a top modifiable risk factor, and its overall impact is most likely
underrepresented.
A significant strength of this study can be found in the GT approach. The study began with
no pre-conceived biases, and findings are reflective of determinants of non-adherence deemed
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important by experts in the field and are evidence based. The relative consistency of top non-
modifiable and modifiable risk factors is noteworthy. This study is replicable, and future stud-
ies could be undertaken to measure consistency of findings.
Finally, the intention of this research was not to provide conclusive evidence that identifies
all determinants of non-adherence for autoimmune diseases. Rather, it is a first step in recog-
nizing common risk factors that can be applied to digital tool development.
Conclusions
According to these findings, adherence outcomes and digital attrition in autoimmunology
patients could be improved if patients were given tailored tools to help them gain greater
understanding of their disease, the role of medications, and information on side effects, and the
role of dose regimen.
Results also indicate that rather than adopting a traditional systems level approach, digital
health might focus on cohorts with heterogeneous needs, and develop tailored interventions
based on individual non-adherence patterns.
Digital health programs focusing on daily diaries, stage-based modules, standardized
reminders and emails have only proven to be moderately successful. A patient’s relationship to
treatment is highly personal, and digital interventions should take advantage of technologies
that enable tailoring for the unique needs of individuals. Digital health programs addressing
other conditions have shown promise, and our evidence indicates that autoimmune patient
cohorts may benefit from tailored and accessible electronic resources.
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